Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

被引:6
作者
Yu, Pengfei [1 ]
Huang, Xingmao [1 ]
Huang, Ling [1 ]
Dai, Gaiguo [1 ]
Xu, Qi [2 ]
Fang, Jingquan [1 ]
Ye, Zeyao [1 ]
Chai, Tengjiao [1 ]
Du, Yian [1 ]
机构
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Gastr Surg, Hangzhou 310022, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
Gastric cancer; Chemotherapy; Hyperthermic intraperitoneal chemotherapy (HIPEC); Peritoneal metastasis; Prognosis; CYTOREDUCTIVE SURGERY; PERITONEAL PERFUSION; OPEN-LABEL; CLASSIFICATION; COMPLICATIONS; CAPECITABINE; CISPLATIN; EFFICACY; TRIAL;
D O I
10.1007/s00432-023-05019-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Currently, there is a lack of an effective strategy for the prevention of peritoneal metastasis (PM) from locally advanced gastric cancer (AGC). This randomized-controlled study aimed to evaluate the outcome of D2 radical resection with hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally AGC patients. Methods All enrolled patients were randomly assigned to receive HIPEC plus systemic chemotherapy (HIPEC group) or systemic chemotherapy alone (non-HIPEC group) after radical gastrectomy. HIPEC was performed intraperitoneally with cisplatin (40 mg/m(2)) within 72 h after surgery, while systemic chemotherapy based on the SOX regimen (S-1 combined with oxaliplatin) was administered 4-6 weeks after radical surgery. Patterns of recurrence, adverse events, 3-year disease-free survival (DFS), and overall survival (OS) were analyzed. Results A total of 134 patients were enrolled in the present study. The 3-year DFS rate was 73.8% in the HIPEC group, which was significantly higher than that in the non-HIPEC group (61.2%, P = 0.031). The 3-year OS rate was 73.9% in the HIPEC group and 77.6% in the non-HIPEC group, with no significant difference (P = 0.737). PM was the most common distant metastasis in both groups. The occurrence rate of PM in the HIPEC group was statistically lower than that in the non-HIPEC group (20.9% vs. 40.3%, P = 0.015). Grade 3 or 4 adverse events occurred in 19 (14.2%) patients, and there was no significant difference between the two groups. Conclusion Radical surgery followed by HIPEC combined with systemic chemotherapy is a safe and feasible strategy for locally AGC patients and could effectively improve DFS and reduce the occurrence of PM. However, more prospective randomized studies with a large sample size are warranted.
引用
收藏
页码:11491 / 11498
页数:8
相关论文
共 50 条
  • [41] Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study
    Xiang, Jinyu
    Gong, Wenjing
    Sun, Ping
    Wang, Xuan
    Liu, Aina
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (06) : 2874 - +
  • [42] Gastric transcatheter chemoembolization combined with systemic chemotherapy vs. systemic chemotherapy alone for patients with advanced gastric cardiac cancer presenting with dysphagia: A case control study
    Li, Zhenfeng
    Xu, Ran
    Sun, Peng
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [43] Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery
    Biao Fan
    Zhaode Bu
    Ji Zhang
    Xianglong Zong
    Xin Ji
    Tao Fu
    Ziyu Jia
    Yinan Zhang
    Xiaojiang Wu
    BMC Cancer, 21
  • [44] Fibrin-Sealant-Delivered Cisplatin Chemotherapy Versus Cisplatin Hyperthermic Intraperitoneal Perfusion Chemotherapy for Locally Advanced Gastric Cancer Without Peritoneal Metastases: A Randomized Phase-II Clinical Trial with a 40-Month Follow-up
    Huang, Ou
    Lu, XiangHong
    Xu, XiangDong
    Shi, Yong
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 71 (02) : 1171 - 1180
  • [45] Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)
    Shen, Jinwen
    Zhu, Xiu
    Du, Yian
    Zhu, Yuan
    Yu, Pengfei
    Yang, Litao
    Xu, Zhiyuan
    Huang, Ling
    Zhang, Yunli
    Zhang, Yanqiang
    Liu, Luying
    Cheng, Xiangdong
    TRIALS, 2021, 22 (01)
  • [46] Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
    Yu, Yuanyuan
    Zhang, Zicheng
    Meng, Qianhao
    Ma, Yue
    Fan, Xiaona
    Sun, Jie
    Wang, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] A Preliminary Study of Single Intraperitoneal Administration of Paclitaxel Followed by Sequential Systemic Chemotherapy with S-1 plus Paclitaxel for Advanced Gastric Cancer with Peritoneal Metastasis
    Imano, Motohiro
    Peng, Ying-Feng
    Itoh, Tatsuki
    Nishikawa, Masayasu
    Satou, Takao
    Yasuda, Atsushi
    Inoue, Keisuke
    Kato, Hiroaki
    Shinkai, Masayuki
    Tsubaki, Masahiro
    Yasuda, Takushi
    Imamoto, Haruhiko
    Nishida, Shozo
    Furukawa, Hiroshi
    Takeyama, Yoshifumi
    Okuno, Kiyokata
    Shiozaki, Hitoshi
    ANTICANCER RESEARCH, 2012, 32 (09) : 4071 - 4075
  • [48] Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites
    Lu, C.
    Li, L.
    Luo, Z.
    Cui, Y.
    Fu, P.
    Zhou, J.
    Ma, N.
    Zhou, Y.
    NEOPLASMA, 2016, 63 (02) : 299 - 303
  • [49] Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study
    Wang, Fuli
    Qu, Aizhong
    Sun, Yinping
    Zhang, Jifeng
    Wei, Benzun
    Cui, Yong
    Liu, Xiao
    Tian, Wei
    Li, Yan
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1124)
  • [50] Can We Reboot the Role of Intraperitoneal Chemotherapy in the Treatment for Gastric Cancer with Peritoneal Carcinomatosis?: A Retrospective Cohort Study Regarding Minimally Invasive Surgery Conjoined with Intraperitoneal plus Systemic Chemotherapy
    Kim, Sungho
    Lee, Chang-Min
    Lee, Danbi
    Kim, Jong-Han
    Park, Sungsoo
    Park, Seong-Heum
    CANCERS, 2022, 14 (09)